18-oxocortisol (18oxoF), which have structural characteristics of both aldosterone and cortisol in their chemical structures, 13 are both synthesized from 11-deoxycortisol as substrate by aldosterone synthase (CYP11B2), although 18OHF can also be produced by 11-β-hydroxylase (CYP11B1). 14, 15 Their production is known to be highly elevated in glucocorticoid-remediable aldosteronism. 16, 17 Furthermore, production of 18OHF and 18oxoF is elevated in patients with PA, especially in APA. 13 The 24-hour urine excretion of these steroids is higher in patients with PA than that in normal subjects and patients with EH. 13, [17] [18] [19] [20] Urinary 18OHF is considered more reliable in terms of subclassification of PA than urinary 18oxoF provided that they have been accurately evaluated by enzyme-linked immunoassay. 20 We recently developed a highly sensitive test to measure 18oxoF based on liquid chromatography tandem mass spectrometry (LC-MS/MS). 21 In this study, we examined the clinical significance of peripheral plasma concentrations of 18OHF and 18oxoF (p18OHF and p18oxoF) by LC-MS/MS in subtype classification of PA.
Methods

Patients and Imaging
From October 2010 to September 2013, 234 patients consisting of 113 patients with CT-detectable macro-APA and 121 patients with BHA, underwent computed tomographic scanning and successful cosyntropin-stimulated AVS. All of the 113 patients with APA underwent adrenalectomy, and diagnostic accuracy was further confirmed by postoperative measurement of plasma aldosterone concentration (PAC) and histopathologic evaluation, including immunohistochemical analysis of steroidogenic enzymes. [22] [23] [24] Twenty-seven patients with CT-undetectable micro-APA were also diagnosed by AVS and underwent unilateral adrenalectomy with their diagnosis being confirmed histopathologically after surgery. Our preliminary study revealed that p18oxoF and 18OHF of patients with micro-APA were as low as those of patients with BHA (data not shown) and therefore, we evaluated mainly patients with APA and BHA in this study. This study was approved by the ethics committee of Tohoku University School of Medicine (number. 2010-359 and number 2010-360) and written informed consent was obtained from all participants. The patients with a plasma aldosterone concentration (PAC)/plasma renin activity ratio (ARR) of >20 (ng/dL per ng/mL per h) after challenge with 50 mg captopril were diagnosed with PA as previously reported. 9 Patients were treated with calcium channel blockers and α 1 -blockers during the PA workup. None of the 234 enrolled patients showed autonomous cortisol secretion, which was confirmed by cortisol concentrations >3.0 μg/dL after an overnight 1-mg dexamethasone suppression test. Among the 249 (234+15) patients with PA studied, 15 (6.0%) with 1-mg dexamethasone suppression test-positive cortisol concentrations (mean±SEM, 6.2±0.54 μg/dL) were excluded from this study. The ratio of such patients with PA who could harbor subclinical cortisol hypersecretion is considered to fall between 21% and 3.9% according to previously reported studies. 22, 23 Blood pressure was measured with Omron Hem 907 (Omron Heathcare Co Ltd, Kyoto, Japan) after >15-minutes rest in a sedentary position, and the average of 3 consecutive measurements was recorded. Peripheral blood samples were collected after the patient stayed in the recumbent position for 30 minutes between 8 and 10 am.
The imaging procedure for CT scanning and its detailed interpretation is described in the online-only Data Supplement.
Reagents and Measurement
Fusaric acid was obtained from Sigma-Aldrich (St. Louis, MO). 18oxoF was kindly provided by Dr Gomez-Sanchez. 18OHF was purchased from Steraloids Inc. (Newport, RI). Cortisol-2 H 4 (F-d4) and aldosterone-2 H 7 (Aldo-d7) were purchased from Isosciences (King of Prussia, PA) and C/D/N Isotopes (Pointe-Claire, Canada), respectively. InertSep Pharma cartridges and InertSep SI cartridges were obtained from GL Sciences (Tokyo, Japan). 4-Dimethylaminopyridine and 2-methyl-6-nitrobenzoic anhydride were purchased from Tokyo Chemical Industry (Tokyo, Japan). LC-MS/MS grade acetonitrile was obtained from Wako Pure Chemicals (Osaka, Japan). All other reagents and solvents were of analytic grade. Plasma renin activity and PAC were measured using commercially available kits as previously reported. 9 We used SPAC-S Aldosterone Radioimmunoassay Kit (TFB, Inc, Tokyo, Japan) for measuring PAC in this study. The intra-assay variability of this assay was 1.8% to 8.3%. This radioimmunoassay of PAC had been standardized ( Figure S1 in the onlineonly Data Supplement; Spearman r=0.9055; P<0.0001) using 90 plasma samples with different aldosterone concentrations confirmed by liquid chromatography tandem mass spectrometry (LC-MS/MS), as we previously reported. 18oxoF was measured by LC-MS/MS as previously reported. 21 Sample preparation for LC-MS/MS measurement of 18OHF was described in the online-only Data Supplement. The intra-assay accuracy and precision were 90% to 111% and 3% to 9%, respectively, for both 18OHF and 18oxoF. Those of the interassay of their steroid metabolites were 87% to 108% and 1% to 10%, respectively. The lower limits of quantification for 18OHF and 18oxoF were 2.5 and 0.25 ng/dL, respectively. Table, baseline aldosterone concentration, baseline ARR, and captopril-challenged ARR were all significantly higher in those with APA (46.6 ng/dL, 363 ng/dL per ng/mL per hour and 233 ng/dL per ng/mL per hour) than those with BHA (18.3 ng/dL, 87.1 ng/dL per ng/mL per hour and 63.0 ng/dL per ng/mL per hour). CT scanning detected 15 APA cases with bilateral adrenal nodules and 30 BHA cases with unilateral nonfunctioning adrenocortical nodules, which also did confirm the superior diagnostic ability of AVS compared with imaging modalities (Table) . Furthermore, AVS findings enabled us to diagnose 27 additional patients with micro-APA (CT-undetectable) during this study. Eight of them turned out to harbor unilateral nonfunctioning nodules in the contralateral adrenal. Thus, CT imaging findings were in agreement with those of AVS in 189 (ie, 261-15-30-27) of 261 patients with PA, that is a little >72% of the study population. This discriminatory value of only CT imaging was not so different from that found in previous studies. [8] [9] [10] [11] [12] We also performed ROC analysis to compare the discriminating ability of serum potassium between APA (CT-detectable) and BHA. Those with BHA were tentatively regarded as control and those with APA as the unilateral tumor group. The value of serum potassium had a significant discriminating ability with an AUC of 0.78 using a cut-off value of 3.85 mmol/L, associated with a sensitivity of 0.785 and specificity of 0.785. The serum potassium concentrations in patients with micro-APA were not significantly different from those in patients with BHA.
Statistical Analysis
Peripheral Levels of 18oxoF and 18OHF
Both p18oxoF and p18OHF were significantly elevated in patients with APA (23.6 and 357 ng/dL) compared with those with BHA (1.89 and 129 ng/dL; Table) . When comparing the averaged peripheral plasma concentrations of these 2 steroids between APA and BHA, the APA/BHA ratio of p18oxoF (12.5) was 5× higher than that of p18OHF (2.77). Comparison between PAC and p18oxoF levels subsequently demonstrated a statistically significant correlation between the above 2 groups, and those with APA showed the most marked correlation (Spearman r=0.5336; P<0.05) compared with those with BHA (Spearman r=0.1987; P<0.05; Figure 2SA and 2SB). In addition, linear regression analysis between peripheral aldosterone and 18oxoF levels also revealed the model was most fitted in those with APA (R 2 =0.6488) compared with those with BHA (R 2 =0.0367; Figure S2A and S2B). In contrast, comparison between peripheral PAC and p18OHF demonstrated a significant correlation in the APA group (Spearman r=0.4886; Figure S2C ) but not in the BHA group ( Figure S2D ). The distribution of p18oxoF showed that the highest level in the BHA group was 6.1 ng/dL, and the minimal value of p18oxoF in the APA group was 1.2 ng/dL ( Figure 1E ). The highest levels of p18OHF, PAC, and ARR in the BHA group were 345 ng/dL, 32.7 ng/dL, and 254 ng/dL per ng/mL per hour, respectively, and their minimal values were 5.7 ng/dL, 8.6 ng/dL, and 20 ng/dL per ng/mL per hour, respectively ( Figure 1F , 1G, and 1H). In 86 of the 113 patients with APA (76%), p18oxoF concentration was above the maximum level (6.1 ng/dL) observed in patients with BHA. In 61 (54%), 56 (50%), and 47 (42%) of patients with APA, PAC, ARR, and p18OHF were higher than the maximum levels observed in patients with BHA. Therefore, p18oxoF was considered to be of the highest diagnostic value for PA subtyping. Furthermore, we examined whether p18oxoF concentration served to differentiate 52 patients with APA whose PAC were ≤32.7 ng/dL, which was the maximum level in patients with BHA. Of particular interest, 34 (65%) of these 52 patients with APA who had p18oxoF concentrations >6.1 ng/dL were considered to require surgery ( Figure 2 ). Therefore, 95 (84%) of the 113 patients with APA could be differentiated by the values of PAC and p18oxoF.
ROC Analyses
Moreover, we measured p18oxoF in patients with EH by excluding PA and any other cause of secondary hypertension. The p18oxoF (1.3±0.2 ng/dL) in 79 patients with EH was significantly lower than that in patients with APA but not significantly different from that in patients with BHA. The highest concentration of p18oxoF in patients with EH was 5.6 ng/ dL, which was lower than the highest value in patients with BHA ( Figure S3 ). Interestingly, there were 52 (43%) of 121 patients with BHA ( Figure 2 ) and 52 (66%) of 79 patients with EH ( Figure S3 ) whose p18oxoF was <1.2 ng/dL, the lowest 18oxoF concentration in patients with APA.
In addition, we measured p18oxoF and p18OHF in 27 patients with micro-APA who underwent adrenalectomy based on their AVS findings and who were clinically and histopathologically confirmed. The levels of both p18oxoF (1.80±0.26 ng/dL) and p18OHF (147±21.4 ng/dL) in these 27 patients with micro-APA were significantly lower than those patients with CT-detectable APA but not significantly different from those in patients with BHA. The highest levels of p18oxoF, p18OHF, PAC, and ARR in patients with micro-APA were 4.8 ng/dL, 483 ng/dL, 24.5 ng/dL, and 245 ng/dL per ng/mL per hour, respectively, and their distributions were almost overlapped with those in patients with BHA ( Figure  S4) . None of these patients with micro-APA with or without contralateral unilateral nonfunctioning adrenocortical nodules had a p18oxoF level >6.1 ng/dL, which has been considered as the cut-off value to recommend adrenalectomy.
Furthermore, we added analyses about the relationship among p18oxoF, AVS lateralization index and somatic KCNJ5 mutations, and we summarized these results in the online-only Data Supplement. 
Discussion
In this study, we measured p18oxoF and p18OHF in 261 (234+27) patients with PA, who were subsequently classified based on the results of AVS into 113 patients with APA, 121 patients with BHA, and 27 patients with micro-APA. In all the 113 patients with APA and 27 patients with micro-APA who underwent adrenalectomy, the diagnosis was further confirmed postoperatively based on PAC and immunohistochemical analysis of steroidogenic enzymes in resected adenomas. [25] [26] [27] We found that p18oxoF was a more reliable diagnostic parameter to differentiate between APA and BHA than p18OHF. The possibility of measuring 18oxoF by LC-MS/MS (lower limit: 0.25 ng/dL) has enabled us to detect a low concentration in peripheral plasma, 21 and to differentiate APA from BHA (or EH) without the need to have patients to collect the 24-hour urine. Thus, this is the first study to demonstrate that the peripheral blood concentrations of 18oxoF measured by LC-MS/MS can clinically differentiate between APA and BHA with a reasonable precision. In particular, 84% of patients with APA had a p18oxoF concentration above 6.1 ng/dL or PAC of >32.7 ng/dL. In this study, patients with APA represented only those with a CT-detectable aldosterenoma and did not include any of the patients with micro-APA. Moreover, this accuracy rate of 84% was obtained based on p18oxoF and CT findings. This is the primary reason why this accuracy rate of 84% was much higher than that found in previous studies. [8] [9] [10] [11] [12] The discriminatory value of CT imaging alone was 72% as described above, which was not so different from that obtained in previous studies. [8] [9] [10] [11] [12] Besides, in 43% of patients with BHA, p18oxoF was <1.2 ng/dL, which was the lowest value found in patients with APA. In addition, further analysis of the 27 patients with micro-APA revealed that 8 (30%) of them harbored contralateral adrenocortical nodules on CT images and the highest p18oxoF and PAC were 4.8 and 24.5 ng/dL, respectively. These values were significantly lower than their respective cut-off values of 6.1 and 32.7 ng/dL. Also, 30 of 121 patients with BHA had CT-detectable unilateral nonfunctioning adrenocortical nodules. Consequently, the evaluation of p18oxoF in such patients might contribute to avoid an unnecessary surgery in an institution where AVS is not available for preoperative routine evaluation of PA patients with unilateral adrenal nodules.
On the basis of the results of this present study, we recommend adding p18oxoF to the diagnostic workup for PA (Figure 3 ). Throughout this systematic clinical workup, we might have been able to limit the use of AVS in 87 patients with PA whose p18oxoF was between 1.2 and 6.1 ng/dL, a range in which patients with APA and BHA were found to overlap after selecting the patients highly suspected of having APA and those with BHA (Figures 2 and 3) .
In this study, the LC-MS/MS intra-assay accuracy and precision were 90% to 111% and 3% to 9% for 18OHF and 18oxoF, respectively. Those of interassay were 87% to 108% and 1% to 10% for 18OHF and 18oxoF, respectively. The lower limits of quantification of 18OHF and 18oxoF were 2.5 and 0.25 ng/dL, respectively. The 3% to 9% precision of LC-MS/MS indicated, therefore, that this method was considered as a reliable mode of measurement in this setting. Further to this, the cut-off value was higher than the lower limit of quantification. Thus, we think that precision of the measurement method was demonstrated by the results obtained. Likewise, the sensitivity and the specificity of the cut-off value were influenced by the precision of the measurement method. Nevertheless, it is entirely true that the 3% to 9% precision of this method indicated that the clinical diagnosis of AP should be carefully performed in patients whose 18OHF and 18oxoF values are around the cut-off value.
18-Hydroxycorticosterone was also reported to help discriminate APA from BHA, especially after posture test. 28 However, Mulatero et al 20 reported that basal levels of 18-hydroxycorticosterone did not help to differentiate PA subtypes in their study and because we wanted to find surrogate markers to discriminate PA subtypes by their basal peripheral blood levels, we selected 18OHF and 18oxoF. Because Figure 3 . Diagnostic flow model based on peripheral aldosterone and 18-oxocortisol levels. Those with confirmed primary aldosteronism (PA) and both an aldosterone level >32.7 ng/dL and a unilateral nodule by computed tomography (CT) undergo adrenalectomy without adrenal venous sampling (AVS). Those with an aldosterone level ≤32.7 ng/dL are divided into 3 subgroups depending on their peripheral 18-oxocortisol level to determine subsequent diagnostic workup steps. APA indicates aldosterone-producing adenoma; ADX, adrenalectomy; BHA, bilateral hyperaldosteronism; GRA, glucocorticoid-remediable aldosteronism; MRA, mineralocorticoid receptor antagonist; p18oxoF, peripheral 18-oxocortisol; PAC, plasma aldosterone concentration; and PCR, polymerase chain reaction.
by guest on October 18, 2017 http://hyper.ahajournals.org/ Downloaded from 18oxoF production was reported to be small but could be localized with CYP11B2, we thought that if we developed a sensitive LC-MS/MS method, we could expect to measure even basal p18oxoF and be able to differentiate APA from BHA. In contrast, 18OHF can be produced by both CYP11B2 and CYP11B1 in the zona glomerulosa and the zona fasciculata, respectively, resulting in higher secretion of 18OHF compared with 18oxoF. 15 In this study, p18OHF was also higher than p18oxoF. However, the ratio of p18OHF between APA and BHA was merely one fifth that of p18oxoF, indicating that the sensitivity of differentiation by p18OHF (0.62) is lower than that by p18oxoF (0.83). Specificity of p18OHF (0.96) about subtyping was reasonably high the same as that by p18oxoF (0.99), and therefore, p18OHF can also be a reliable diagnostic tool to discriminate APA from BHA.
A major drawback of measuring p18oxoF by LC-MS/MS is the cost but this ( ≈150 US dollars per sample) is far less expensive than that of AVS, which amounts to ≈10 000 US dollars in the United States. Moreover, we propose a diagnostic strategy for APA by precisely measuring p18oxoF after selecting patients with APA according to PAC from among confirmed patients with PA( Figure 3) . Through this approach, we should be able to reduce the medical cost by not only omitting an unnecessary AVS procedure but also by limiting p18oxoF measurement. Therefore, we could reconfirm the usefulness of this strategy, which might have enabled 95 (ie, 61+34) of the 113 patients with APA (84%) to undergo surgery after the detection of unilateral adrenal nodules by CT scanning without subjecting them to AVS, and 52 of the 121 patients with BHA (43%; p18oxoF <1.2 ng/dL) to receive pharmacological treatment with mineralocorticoid receptor antagonists without performing AVS. Furthermore, the highest concentration of p18oxoF in patients with EH was 5.6 ng/dL (<6.1 ng/dL), and in 52 (66%) of 79 patients with EH p18oxoF was <1.2 ng/dL, the lowest p18oxoF in patients with APA. Therefore, these results indicated that higher or lower levels of 18oxoF could serve to predict the presence or absence APA without further confirmatory evaluation in the patients with high ARR, but a further larger study will be required to confirm this interesting hypothesis.
Perspectives
The results of this large study revealed that measurement of 18oxoF in peripheral blood by LC-MS/MS should enable us to improve the clinical algorithm for PA, potentially omitting unnecessary AVS, which is a expensive and invasive procedure, and requires the dedicated work of experienced radiologists. Yet, AVS is still the only reliable method for determining the cause of hyperaldosteronism at specialized institutions where skillful radiologists make efforts to perform successful catheterizations. 11, 29 In particular, AVS is the only way to distinguish a CT-undetectable micro-APA from BHA, 8, [30] [31] [32] even though no standardization of protocols has been performed yet. 11, 33 In this study, p18oxF levels in patients with micro-APA were completely overlapped with those in patients with BHA, and AVS is therefore considered critical in differentiating these 2 subtypes. This was a monocentric, retrospective study in Japanese patients. A prospective, multi centric study in centers treating different ethnicities is necessary to confirm the results.
Supplemental Methods
Methods of computed tomography scanning:
The computed tomography (CT) scanner used in this population of the patients was an Aquilion 64-detector row helical CT scanner (Toshiba, Tokyo, Japan). Four-phase dynamic scans were obtained with the following parameters: 0.5 second per rotation, 0.5 mm collimation, and 20.5 mm/sec table increment (pitch factor = 0.64). Before scaning, 100 mL of a non-ionic contrast media containing 300 mg of iodine per milliliter was injected into an antecubital vein of the patients at a rate of 4.0 mL/sec. The scan delay was set by means of an automatic triggering system (SureStart; Toshiba). When the attenuation value at the level of the ascending aorta reached the preset threshold (CT value of the abdominal aorta on plain CT plus 100HU{Haunsfield Unit}), early-arterial-phase scanning was automatically initiated.
Late-arterial-phase scanning also started at 13 seconds after the completion of the early arterial scanning. Venous phase and delayed-phase scanning followed at 70 seconds and 3 minutes after the start of the contrast injection, respectively. Transverse sections were reconstructed with a 0.5-mm section thickness at 0.5-mm intervals. When evaluating the right adrenal vein (RAV), the reconstruction field of view was set to the area around the aorta, inferior vena cava (IVC) and both kidneys. This methodology has been used in our other publications.
1,2
Methods of CT interpretation:
In this study, images were interpreted using a stand-alone workstation (AQ station; Terarecon, Tokyo, Japan). We used a multiplanar reformation (MPR) display mode which could allow simultaneous cine-mode observation of axial, coronal, and saggital MPR images to evaluate the RAV. The image analysis is based on Radiology report formulated before the analysis of the hormone level. At least two board certified radiologists were involved in interpretation of the findings in a blind fashion and when interobserver differences occurred, these diagnostic radiologists evaluated the images together to reach the consensus. Moreover, they carefully reanalyzed the images of the contralateral adrenal of the cases with the radiology reports of unilateral nodules in the blind fashion but there were no differences between the first and second reports. This is because at least two radiologists were involved in formulating the reports of adrenal images when generating the first report through reconstituting continual images by the latest imaging software. This methodology has been used in our other publications.
1-3
Sample preparation for LC-MS/MS measurement of 18OHF
The plasma samples were prepared as previously reported. 4 F-d4 (0.25 ng) and Aldo-d7 (0.05 ng) were added to plasma (0.1 mL) as internal standard. Acetonitrile (0.2 mL) was added to the sample and the mixture was centrifuged to precipitate proteins. The diluted supernatant was applied to an InertSep Pharma cartridge, and the steroidal fraction was eluted with 80% acetonitrile (1 mL). After the eluate was evaporated to dryness, the residue was treated with 0.25 ml of 35% HCl in ethanol (1:5, vol/vol) at room temperature for 30 min. Derivatization of 18OHF, F-d4, 18oxoF, and Aldo-d7 was performed according to the mixed anhydride method using fusaric acid. The resulting mixture was transferred to an InertSep SI cartridge and then washed successively with 50% hexane-ethyl acetate and 50% ethyl acetate-acetonitrile. The desired fraction was eluted with 50% ethyl acetate-acetonitrile (1.5 mL) and evaporated. The residue was dissolved in 40% acetonitrile (0.1 mL) and subjected to LC/MS/MS.
Supplemental Results
The relationship among p18oxoF, AVS lateralization index (LI) and somatic KCNJ5 mutations LI (16.5 ± 2.0, mean ± SEM) after ACTH stimulation in 113 APA cases was significantly correlated with p18oxoF levels (Spearman's r = 0.2681, P <0.05). We compared the p18oxoF levels of thirty-four somatic-KCNJ5-mutated patients with those of fourteen wild type patients in our study. The results demonstrated that the p18oxoF levels of somatic-KCNJ5-mutated cases (35.3 ± 9.1 ng/dL, mean ± SEM) were not significantly different from those of wild type patients (20.3 ± 5.4 ng/dL, mean ± SEM) (P=0.090 by unpaired t test with Welch's correction), possibly due to the relatively small number of patients examined in this particular study. To our great regret, we could secure the informed consent for evaluating somatic KCNJ5 mutations from only 48 APA of the 113 APA patients examined in this study. Yet, the p18oxoF level in patients bearing a somatic-KCNJ5 mutation tended to be higher than that in wild type patients but further studies are required to examine whether p18oxoF can predict somatic-KCNJ5 mutations of individual patients.
